The two firms will co-develop and co-commercialize three Daiichi ADCs globally outside Japan in a deal the Japanese firm said would allow “more aggressive development plans targeting broader patient populations.”
In another big endorsement of its proprietary R&D platform, Daiichi Sankyo Co., Ltd. has announced a huge new global deal for three antibody-drug conjugate (ADC) candidates with Merck & Co., Inc., worth $4bn upfront ($3bn immediately upon execution) and up to $22bn in total.
The agreement covers the Japanese firm's anti-HER3 ADC patritumab deruxtecan (HER3-DXd/U3-1402), anti-B7-H3 ADC ifinatamab deruxtecan (I-DXd/DS-7300) and CDH6-targeting ADC raludotatug...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
